Monthly Archives: March 2014

Let’s face it, biotech entrepreneurs are innovation junkies.  We desperately want to deploy the most novel technologies to solve difficult problems in medicine and deliver new, life changing medicines for patients who need our help.  Independent of additional factors that

Today’s biopharma industry has a richer and more exciting late stage pipeline of compelling new therapeutics than its had in years, drawing lots of enthusiasm from analysts and investors.  Goldman Sachs (GS) recently published a report on the “10 drugs

Despite many decades of success, small molecule drug discovery appears to be increasingly challenged.  The likelihood of approval of a small molecule at phase 1 is approximately half that of a biologic; pharma companies have shifted their pipelines dramatically towards

Five years ago I stepped into my first (and so far only) CEO role. It seems impossible that it was five years ago but I definitely still remember many moments from my rookie year as a CEO – both successes

As an early stage biotech investor, the future of the industry and its structure are clearly important things to think about – especially since most of the drug programs our new startups are working on won’t get launched, if they

Humans are supremely lousy at evaluating risk. We get nervous when we fly but not when we drive. We worry about terrorist attacks when we’re far more likely to die in our own bathrooms. We flock to buy tickets for